CCL22: A Protein Involved in T Cell Regulation and Immune Response

Target Name: CCL22

NCBI ID: G6367

CCL22

CCL22: A Protein Involved in T Cell Regulation and Immune Response

CCL22 (C chemokine STCP-1) is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, and nail beds. It is a member of the chemokine family, which are a group of proteins that are involved in the regulation of cellular responses to various stimuli. STCP-1 is a specific chemokine that is produced by dendritic cells, which are a type of immune cell that are responsible for presenting antigens to T cells.

One of the functions of CCL22 is to attract T cells to the site of an infection or inflammation. This is accomplished through the interaction between CCL22 and the T cell receptor, which is a protein that is found on the surface of T cells. When a T cell encounters CCL22, it is able to bind to the protein and receive a signal that tells it to move towards the site of the infection or inflammation. Once it reaches the site, the T cell can then respond to the presence of the infection or inflammation by engaging in an attack on the affected cells.

CC chemokine STCP-1 has also been shown to play a role in the regulation of immune cell responses to various types of infections and injuries. For example, studies have shown that CCL22 is involved in the regulation of the movement of immune cells towards the site of an infection, as well as the production of antibodies by these cells. It has also been shown to play a role in the regulation of the inflammatory response, as it has been shown to be involved in the production of pro-inflammatory cytokines by immune cells.

In addition to its role in immune regulation, CCL22 has also been shown to have potential as a drug target. Several studies have shown that CCL22 can be effectively targeted by small molecules, such as those that are derived from natural compounds or that are synthesized artificially. These small molecules have been shown to be able to inhibit the activity of CCL22, which could potentially make them useful as therapeutic agents for a variety of diseases.

One of the challenges in the development of CCL22 as a drug target is the fact that it is produced by a wide variety of cells in the body, which makes it difficult to predict how a particular drug treatment may affect its levels in different tissues. Additionally, the regulation of CCL22 by immune cells makes it difficult to predict how a particular drug treatment may affect its levels in these cells. However, researchers are continuing to study the role of CCL22 as a drug target, and are working to develop strategies for targeting its activity in specific tissues and cells.

In conclusion, CCL22 is a protein that is expressed in a variety of tissues throughout the body and is involved in the regulation of cellular responses to various stimuli. It has also been shown to play a role in the regulation of immune cell responses to various types of infections and injuries. As a result, CCL22 is a potential drug target for a variety of diseases. Further research is needed to fully understand its role as a drug target and to develop effective therapies that can target its activity in specific tissues and cells.

Protein Name: C-C Motif Chemokine Ligand 22

Functions: May play a role in the trafficking of activated/effector T-lymphocytes to inflammatory sites and other aspects of activated T-lymphocyte physiology. Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T-lymphocytes and a potent chemoattractant for chronically activated T-lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active

The "CCL22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets